Sponsor
National Cancer Institute (NCI)
Status
Not yet recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT05630794
This phase I trial tests the safety, side effects, and best dose of Akt/ERK Inhibitor ONC201 (ONC201) in preventing colorectal cancer in patients with familial adenomatous polyposis (FAP) or a history of multiple polyps. ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Intervention
Biospecimen Collection, Biopsy, Colonoscopy, Sigmoidoscopy, Questionnaire Administration, Dordaviprone
Condition
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Investigators
Alexander G Raufi, Paul E. Wise, Peter P. Stanich, Elena M. Stoffel, Carol A. Burke